Search

Your search keyword '"Mitchell Liu"' showing total 152 results

Search Constraints

Start Over You searched for: Author "Mitchell Liu" Remove constraint Author: "Mitchell Liu"
152 results on '"Mitchell Liu"'

Search Results

1. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET

2. Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

3. Mathematical prediction with pretreatment growth rate of metastatic cancer on outcomes: implications for the characterization of oligometastatic disease

4. Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report

5. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

6. Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors

7. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

8. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

9. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases

10. Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer

11. Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial

13. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial

14. Four‐dimensional dose calculations for dynamic tumour tracking with a gimbal‐mounted linear accelerator

15. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial

16. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) - Extended Long-Term Outcomes

17. Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapy

18. Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial

19. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial

20. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET)

21. 65: Predictors of Early Polymetastatic Relapse Following Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial

23. 36: Progression-Free Survival and Local Control Following Stereotactic Ablative Radiotherapy for Up to Five Oligometastases: An Analysis from the Population-Based Phase II SABR-5 Trial

24. Implementation of Single-Fraction Lung Stereotactic Ablative Radiotherapy in a Multicenter Provincial Cancer Program During the COVID-19 Pandemic

25. Thecal Sac Contouring as a Surrogate for the Cauda Equina and Intracanal Spinal Nerve Roots for Spine Stereotactic Body Radiation Therapy (SBRT): Contour Variability and Recommendations for Safe Practice

26. Is SABR cost-effective in oligometastatic cancer?:An economic analysis of the SABR-COMET randomized trial

27. 139: Adoption and Implementation of Single Fraction Lung Stereotactic Ablative Radiotherapy in a Multi-Centre Provincial Cancer Program During the COVID-19 Pandemic

29. Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients With Painful Spinal Metastases: A Phase 3, Randomized Controlled Trial

30. Comparison of Rapid to Standard Volumetric Modulated Arc Therapy for Palliative Radiotherapy in Lung Cancer Patients

31. Re-irradiation of Spinal Metastases

32. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET Phase II randomized trial

33. Re-irradiation volumetric modulated arc therapy optimization based on cumulative biologically effective dose objectives

34. 2: Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to Five Oligometastases: Preliminary Results of the SABR-5 Trial

35. 23: Cost-Effectiveness of Sabr in Oligometastatic Cancer: An Economic Analysis Based on Long-Term Results of the SABR-Comet Randomized Trial

36. CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases

38. 201: Stereotactic Ablative Radiotherapy (SABR) for Oligometastases: Risk Stratification Using Positional Uncertainty

39. International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT)

40. In Reply to Ryu

41. P21.05 Overall Survival by PD-L1 Status in Stage III NSCLC Following Implementation of Durvalumab: The Real-World Application of PACIFIC

43. 8: Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-Comet Randomized Trial

44. Impact of oligometastatic disease on survival in ER positive breast cancer: A population-based analysis

45. Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions

46. Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy

47. Commentary: Local Control and Toxicity of Multilevel Spine Stereotactic Body Radiotherapy

48. 92 Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-COMET

49. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-Comet

50. Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion‐positive lung cancer patient

Catalog

Books, media, physical & digital resources